HDAC2 and lung carcinoma: In lung cancer, low-dose butyrate enhances tumour growth and metastasis through extracellular matrix remodelling, upregulation of MMP15, and HDAC2-dependent activation of the oncogenic lncRNA H19, which also promotes M2 macrophage polarization47–50.